Biomedical Engineering Reference
In-Depth Information
18. Kay, M.A., Glorioso, J.C. and Naldini, L. (2001) Viral vectors for gene therapy: the art of turning
infectious agents into vehicles of therapeutics.
Nature Medicine
,
7
(1), 33-40.
19. Hu, W.S. and Pathak, V.K. (2000) Design of retroviral vectors and helper cells for gene therapy.
Pharmacological Reviews
,
52
(4), 493-511.
20. Coffin, J.M., Hughes, S.H. and Varmus, H.E. (1997)
Retroviruses
, Cold Spring Harbor Laboratory
Press, New York.
21. Riviere, I., Brose, K. and Mulligan, R.C. (1995) Effects of retroviral vector design on expression
of human adenosine deaminase in murine bone marrow transplant recipients engrafted with
genetically modified cells.
Proceedings of the National Academy of Sciences of the United States
of America
,
92
(15), 6733-6737. Describes the pMFG retroviral vector.
22. Markowitz, D., Goff, S. and Bank, A. (1988) A safe packaging line for gene transfer: separating
viral genes on two different plasmids.
Journal of Virology
,
62
(4), 1120-1124.
23. Lewis, P.F. and Emerman, M. (1994) Passage through mitosis is required for oncoretroviruses
but not for the human immunodeficiency virus.
Journal of Virology
,
68
(1), 510-516.
24. Sanders, D.A. (2002) No false start for novel pseudotyped vectors.
Current Opinion in Biotech-
nology
,
13
(5), 437-442.
25. Kafri, T., van Praag, H., Ouyang, L.
et al
. (1999) A packaging cell line for lentivirus vectors.
Journal of Virology
,
73
(1), 576-584.
26. Mitta, B., Rimann, M., Ehrengruber, M.U.
et al
. (2002) Advanced modular self-inactivating
lentiviral expression vectors for multigene interventions in mammalian cells and
in vivo
trans-
duction.
Nucleic Acids Research
,
30
(21), e113.
27. Buchschacher, G.L. Jr. and Wong-Staal, F. (2001) Approaches to gene therapy for human immun-
odeficiency virus infection.
Human Gene Therapy
,
12
(9), 1013-1019.
28. Linial, M. (2000) Why aren't foamy viruses pathogenic?
Trends in Microbiology
,
8
(6), 284-289.
29. Trobridge, G., Josephson, N., Vassilopoulos, G.
et al
. (2002) Improved foamy virus vectors with
minimal viral sequences.
Molecular Therapy
,
6
(3), 321-328.
30. Bauer, T.R. Jr., Allen, J.M., Hai, M.
et al
. (2008) Successful treatment of canine leukocyte
adhesion deficiency by foamy virus vectors.
Nature Medicine
,
14
(1), 93-97.
31. Berns, K.I. and Giraud, C. (1996) Biology of adeno-associated virus, in Adeno-Associated Virus
(AAV) Vectors in Gene Therapy (eds K.I. Berns and C. Giraud), Springer-Verlag, Berlin, pp.
1-24. An overview of the biology of AAV.
32. Lai, C.M., Lai, Y.K. and Rakoczy, P.E. (2002) Adenovirus and adeno-associated virus vectors.
DNA and Cell Biology
,
21
(12), 895-913.
33. Dong, J.Y., Fan, P.D. and Frizzell, R.A. (1996) Quantitative analysis of the packaging capacity
of recombinant adeno-associated virus.
Human Gene Therapy
,
7
(17), 2101-2112.
34. Zaiss, A.K., Liu, Q., Bowen, G.P.
et al
. (2002) Differential activation of innate immune responses
by adenovirus and adeno-associated virus vectors.
Journal of Virology
,
76
(9), 4580-4590.
35. Xiao, W., Chirmule, N., Berta, S.C.
et al
. (1999) Gene therapy vectors based on adeno-associated
virus type 1.
Journal of Virology
,
73
(5), 3994-4003.
36. Chirmule, N., Xiao, W., Truneh, A.
et al
. (2000) Humoral immunity to adeno-associated virus
type 2 vectors following administration to murine and nonhuman primate muscle.
Journal of
Virology
,
74
(5), 2420-2425.
